History

AstraZeneca India was established in 1979. It is headquartered in Bengaluru, Karnataka. AstraZeneca Pharma India Limited (APIL) is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom. APIL is, hence, an operating company and is engaged in the manufacturing, sales and marketing activities of the group in India. Its R&D centre in the Bengaluru ‘Avishkar’ campus is a part of its global R&D operations. The company got listed on August 17, 1982. In 2003, the company launched an Oncology product, Arimidex, for the management of breast cancer. However, India’s National Pharmaceutical Pricing Policy of 2012 brought 348 medicines under price control. 15 SKUs across 8 brands of APIL were covered under that list. In FY 2014-15, APIL made a strategic entry into into 3 Distribution Services Agreements under which APIL, Dr Reddy's Laboratories and Sun Pharma will co-promote, market and distribute Saxagliptin, Dapagliflozin and Ticagrelor under different brand names in the Indian market. However, the same year, the company closed the API production unit in Yelahanka, Bangalore. In FY 2017, APIL aligned its portfolio to AstraZeneca's global therapeutic strategic core priority in core areas of Cardio-Metabolism, Oncology and Respiratory. As a part of this process, certain brands were divested in the areas of Antibiotics, Local Anaesthesia, Maternal Health Care and others. In October 2019, the company launched Lynparza, which later got the approval to be the first-line treatment of Ovarian Cancer and also for the treatment of metastatic castrate-resistant prostate cancer with HRR mutations. It launched its new product in the Hematology segment, Calquence. In 2022-23, Fasenra, the first Biologic from AstraZeneca to treat Severe Eosinophilic Asthma (SEA) was given to more than 400 Patients.

Business Segments

The company is engaged in the manufacture, distribution and marketing of pharmaceutical products. It also supplies clinical trials and marketing support services to an overseas group company. For internal reporting purposes, management has organised the Company into a single reportable segment, i.e. the Healthcare segment. Their core priority is on the following:

1. Cardiovascular- This relates to medical solutions related to the heart and blood vessels.
2. Renal and Metabolism- This relates to kidneys and the overall alimentary and excretory system.
3. Oncology- This is related to cancer cure.
4. Respiratory- This relates to the solutions for the respiratory system.
5. Rare diseases- This is one of the areas where the most innovative medicines and supporting technologies are required.
6. Biopharmaceuticals- This involves producing biological organisms that can act as medical solutions.

Subsidiaries The company does not have any subsidiaries.

Key Personnel

Sanjeev Panchal, Country President and Managing Director Mr Panchal is the Country President and MD of AstraZeneca India (Plc). In previous role as CP for AZ Malaysia, he was instrumental in transforming the business to achieve double-digit growth, outpacing the market. He was also a Vice President at PhAMA, i.e. an industry association. He was in the Board of Directors for the British Malaysia Chamber of Commerce, where he actively chaired the Malaysia Cancer Care Coalition.

Corporate Actions

The company has performed the following corporate actions in the recent past: Stock Split The company split its stock from a face value of ₹10 to ₹2 with a record date of June 22, 2006. Mergers and Acquisitions

• In December 2013, AstraZeneca announced the purchase of Bristol Myers Squibb's 50% stake in AstraZeneca's and BMS's joint diabetes enterprise.